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Nerve growth factor gene therapy improves bone marrow sensory innervation 
and nociceptor-mediated stem cell release in a mouse model of type 1 diabetes 
with limb ischaemia  
 
ESM - Methods  
 
Materials: unless otherwise stated, all reagents and chemicals have been purchased 
from Sigma-Aldrich, Gillingham, Dorset, UK. 
 
Induction of diabetes and LI 
The housing, care and procedures in all mice (Mus musculus) used in these studies 
was in accordance with and under license of the Animals (Scientific Procedures) Act 
1986 (London, United Kingdom), and conform to the Guide for the Care and Use of 
Laboratory Animals published by the U.S. National Institutes of Health (Publication No. 
85–23, revised 1996). The study received local institutional review board (University 
of Bristol, Bristol, United Kingdom) approval. The mice were housed in groups of 2-6 
animals in an enriched environment within a biosecure unit, fed with EURodent Diet 
22% (5LF5, LabDiet, St. Louis, MO, USA) and given water ad libitum. All surgery was 
performed using aseptic conditions under isoflurane anaesthesia, with buprenorphine 
analgesia. 
Type 1 diabetes was induced in male 7-weeks old CD1 mice (Hsd:ICR(CD-1®), 
obtained from Harlan, Bicester, UK) by intraperitoneal injection of streptozotocin (STZ, 
40 mg/kg body weight per day for 5 days) [1-3]. STZ-induced diabetic mice develop a 
form of neuropathy like that seen in type 1 diabetic patients [4-6]. Age-matched male 
CD1 mice injected with STZ-vehicle were used as non-diabetic (ND) controls.   
Unilateral limb ischaemia (LI) was induced in mice under isoflurane anaesthesia, as 
described [7].  
 
In vivo gene therapy and samples harvesting 
The experimental protocol is summarised in ESM Fig. 2. Adenoviral vectors carrying 
either the V5-tagged human NGF or β-GAL were produced as previously described 
[8]. The presence of the V5-tag allows easy tracking of the human protein produced 
by the Adenovirus. Two weeks after the first STZ injection, diabetic mice were injected 
with either Ad.hNGF or Ad.βGal via the tail vein (total dose of 1.5 × 109 viral particles 
in 100 μL). Age-matched nondiabetic mice were injected with Ad.βGal and used for 
reference. At sacrifice (16 weeks post gene transfer), bone marrow (BM) from tibias 
and femurs and spinal cord were collected for histological analyses.  
LI ischaemia was induced as described above 13 week after gene delivery with follow-
up for 21 days. At sacrifice (0, 1, 3, 7, 14, 21 days after LI), peripheral blood (PB) and 
bone marrow (BM) from tibias and femurs were collected for assessment of 
neuropeptide levels and flow cytometry analysis of cell antigenic profile. Hindlimb 
muscles (ischaemic and contralateral) were collected for assessment of vascular 
density. 
An additional set of CD1 male mice (without diabetes or LI) were injected with 
Ad.hNGF or Ad.βGal via the tail vein (total dose of 1.5 × 109 viral particles in 100 μL). 
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Plasma was collected at sacrifice 3 days later for assessment of hNGF 
overexpression.  
 
Immunohistochemistry and immunofluorescence microscopy 
Samples harvesting and processing. Femoral bones were collected and cleaned from 
surrounding tissues, rinsed with phosphate-buffered saline (PBS), fixed with 4% w/v 
PFA for 24 hours at 4˚C and decalcified in 10% v/v formic acid for 48 hours at 4˚C. 
Then, after a brief post-fixation with 4% PFA for 4 hours at 4˚C, the bones were rinsed 
with PBS and processed for paraffin embedding. The same protocol has been applied 
to spinal cord samples. Hindlimb muscles were fixed with 4% w/v PFA for 16 hours at 
4˚C and paraffin-embedded. Four µm-thick longitudinal sections were prepared for 
histological evaluation. For all antigens, heat-based antigen retrieval was performed 
by microwave (3 min x 3, 800W), either in sodium citrate buffer 0.01 mol/l, pH=6, or 
0.05% v/v Tween-20 Tris/EDTA buffer, pH 9. For phospho-rpS6, antigen-retrieval was 
performed using a controlled-temperature water-bath (sodium citrate buffer 0.01mol/l, 
98 C, 10 min). 
Immunohistochemistry: For light microscopy assessment (visualised using 
diaminobenzidine (DAB) and alkaline phosphatase (AP)), endogenous peroxidase 
activity was blocked using H2O2 3% v/v. REAL EnVision/HRP, Rabbit/Mouse (ENV) 
(Dako, Santa Clara, CA, USA) was used for detecting the primary antibodies, in 
accordance with the protocols described in ESM Table 1. The reactions were revealed 
by a solution (1:50) of REAL DAB+ Chromogen and REAL Substrate Buffer (Dako, 
Santa Clara, CA, US). Nuclei were stained with Mayer's haematoxylin. All staining 
steps were performed at 15-25°C.  
Immunofluorescence: Sections were blocked with 10% v/v non-immune normal goat 
serum (Cell Signalling Technology, London, UK). Sections were then incubated with 
primary and secondary antibodies as shown in ESM Table 1. Secondary antibodies 
were either conjugated directly with AlexaFluor or with streptavidin followed by an 
AlexaFluor step. All antibodies have been diluted with 5% v/v non-immune normal goat 
serum. Secondary antibodies were purchased from LifeTechnologies (Thermo Fisher 
Scientific, Waltham, MA, USA). Nuclei were stained with DAPI (1:1000 v/v in PBS) for 
2 min, and slides were mounted with Fluoromount-G (Thermo Fisher Scientific). 
Quantification: Bone marrow (BM) neuronal fibres were expressed as number/mm2. 
NGF and substance P (SP) positive staining in BM and muscles was expressed as the 
percentage of the total area assessed. Capillary and arteriole densities were 
expressed as number of vascular profiles/mm2. A minimum of 10-15 images taken 
randomly with a 100-200x total optical magnification was analysed. 
 
Plasma isolation  
PB was collected with EDTA as an anticoagulant and kept on ice until processed. 
Samples were centrifuged for 15 min at 1000 x g at 4°C. Plasma was aliquoted and 
stored at -80°C for subsequent analyses using ELISA assays. 
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ELISA assays 
ELISA assays for hNGF (Cloud-Clone Corp., Katy, TX, USA) and pro-hNGF 
(CUSABIO, Houston, TX, USA) were performed according to manufacturer 
instructions on plasma collected from animals 3 days post-gene transfer to assess the 
levels of the circulating proteins. All samples were assayed in duplicates. This was 
used also to confirm that the mature hNGF was the only form of the recombinant 
protein. 
ELISA for SP (Cayman Chemical Company, Ann Arbor, Michigan, USA) was 
employed to detect SP levels in mice BM, plasma, and ischaemic adductor muscles. 
Briefly, samples were diluted in 2M acetic acid, fractionated with C-18 reverse-phase 
single-use columns (Cayman Chemical Company), and concentrated under vacuum. 
Quantification of SP was performed by measuring the changes in the absorbance of 
nitrobenzoic acid at 412 nm.  
 
Competitive assay to check specificity of the anti-NGF antibody  
A peptide competition assay was performed to rule out non-specific binding of the anti-
NGF antibody to other proteins in the mouse tissues. The NGF peptide was purchased 
from Abcam (Cambridge, UK) (Ab154297). This peptide was recommended by the 
vendor to block the anti-NGF antibody Ab52918. According to manufacture 
instructions, the antibody was incubated with five times excess blocking peptide by 
weight in blocking solution (PBS + 1% w/v BSA), for 30 min at RT, with gentle agitation. 
A tube with the antibody but without peptide served as control. The staining of the BM 
tissue was performed following the normal protocol using the blocked and control 
antibody on two different slices of the same samples. 
 
Culture and characterisation of PC12 cells 
PC12 cells were cultured in DMEM containing 1g/l Glucose + Glutamine, 10% v/v FBS 
and pen/strep and passaged at confluence every 3 days. For phenotypic 
characterisation, cells were fixed with 4% w/v PFA for 15 min at 15-25°C and 
permeabilised using 0.1% TritonX for 5 min as required. After blocking with 10% v/v 
normal goat serum (Cell Signalling Technology), antibodies were incubated for 16 h 
at 4°C (as reported in ESM Table 1). Alexa488-conjugated secondary antibodies 
raised in goat were used to visualise the staining, and the nuclei counter-stained using 
DAPI. Cells were analysed at a x200 magnification.  
 
Rat fibroblasts transduction and collection of conditioned media 
Primary rat fibroblasts were cultured in DMEM containing 1g/l glucose with glutamine, 
10% v/v FBS and pen/strep, and passaged at confluency (̴ 3 days).  Cultures that were 
80% confluent were transduced with either Ad.hNGF or Ad.βGal at a total dose of 5 × 
107 viral particles/ml. Cells not transduced served as control (NV, no virus). After 48h, 
the conditioned media (CM) was centrifuged for 10 min at 1000 x g at 4°C to remove 
floating cells/debris and frozen for subsequent studies with PC12 cells. An aliquot of 
medium was used to check the expression of the human NGF using western blotting. 
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A further aliquot was used to measure the amount of NGF and proNGF using ELISA 
assays.   
 
Biological assays on PC12 cells exposed to the CM from NGF-transduced 
fibroblasts  
PC12 cells were maintained under basal (BG, 5 mmol/l) or high (HG, 30mmol/l) D-
Glucose. Mannitol (25mmol/l) was used as osmotic control when required.  
For signalling experiments, PC12 pre-conditioned for 48h with BG or HG media were 
exposed to the fibroblasts CM (NV, hNGF, βGAL) for 30 min and total cell extracts 
were collected for Western Blotting.  
For Caspase 3/7 apoptosis assay, PC12 were incubated for 48h with the fibroblasts 
CM in the presence of either BG or HG or Mannitol. At the end of this incubation time, 
the Caspase Glo 3/7 Assay (Promega, Madison, Wisconsin, USA) was used to 
measure caspase activity. This was quantified as relative luminescence units (RLU) 
and is expressed as fold change compared with the BG-NV group, using 4 replicates 
per group.  
For neuronal differentiation and neurites outgrowth experiments, low density PC12 
were incubated for 72h with the fibroblasts CM in the presence of either BG or HG. At 
the end of the protocol, images were snapped using a x 200 magnification. The total 
neurites length per cell was measured as an index of neurites outgrowth (N=50 cells 
randomly measured in 3-4 different optical fields), while cells presenting at least one 
axon longer than the cell body were considered as differentiated “neuron-like” cells 
and expressed as a percentage of the total number of cell (per each group, N=250 to 
300 cells analysed in 4 different optical fields).   
For all experiments, fibroblasts CM was diluted 1:10 with fresh culture media, with 
appropriate adjustment for the final level of glucose or mannitol. The final hNGF 
concentration given to the PC12 cells was 540 pg/ml, as measured by ELISA assay. 
 
Proteins extraction and western blotting 
Total proteins from cells were obtained using RIPA lysis buffer supplemented with 
protease and phosphatase inhibitors cocktails. In addition, CM from cells was collected 
for measuring secreted proteins. This was centrifuged for 10 min at 1000 x g at 4°C to 
remove floating cells/debris and supplemented with Laemmli loading buffer. The 
protein concentration in cell extracts was determined using the BCA Protein Assay Kit 
(Thermo Fisher Scientific). Equal amounts of protein samples (10-15μg) were 
prepared in Laemmli loading buffer, incubated for 8 min at 98°C, resolved on 8-12% 
SDS-PAGE according to the proteins MW and transferred onto 0.2 μm PVDF 
membranes (Bio-Rad, Hercules, California, USA). Membranes were blocked using 5% 
w/v non-fat dried milk in Tris-buffered saline (TBS) supplemented with 0.05% v/v 
Tween-20 (TBS-T) for 2 h at 15-25°C. Primary antibodies - listed in ESM Table 1 - 
were incubated for 16h at 4°C using 5% w/v BSA in TBS-T. Secondary antibodies - 
listed in ESM Table 1 - were incubated for 1h at 15-25C using 5% w/v non-fat dried 
milk in TBS-T. β-tubulin was used as loading control. Membrane development was 
performed by an enhanced chemiluminescence-based detection method (ECL™ 
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Prime Western Blotting Detection Reagent, GE Healthcare, Chicago, Illinois, USA) in 
a ChemiDoc-MP system (Bio-Rad). Proteins with similar molecular weight were 
assessed on different gels. When necessary, no more than 2 stripping procedures 
were performed in the same membrane (RestoreTM Plus Western Blot Stripping 
Buffer, Thermo Scientific). All samples to be compared were loaded on the same gel 
for densitometry analysis. Data were analysed using the free ImageJ software to 
determine optical density (OD) of the bands. The OD readings of phosphorylated 
proteins were expressed as a ratio relative to non-phosphorylated protein (N=1 
replicate). Final data are showed as the fold change of the BG-NV group (considered 
to be the basal control). 
 
Flow cytometry  
Analyses of progenitor cells in PB, BM and adductor muscles of mice were conducted 
using multicolour flow cytometry.  
Cell collection. Freshly harvested cells were washed with ice-cold Hank’s balanced 
salt solution containing 0.5% w/v BSA and 0.02% w/v sodium azide. Adductor muscles 
were harvested, minced with fine scissors and placed into a digest solution of 
Collagenase A 100 µg/µl (Roche, Basel, Switzerland), Dispase II (1X) 2.4 U/ml 
(Roche), DNase I 10 mg/ml (Roche), BSA 10% w/v, CaCl2 50 mmol/l, MgCl2 1 mol/l in 
PBS at 37oC for 1 h, triturated through 40μm diameter nylon mesh and washed with 
0.2% w/v BSA + 0.1% w/v DNAse I in PBS. 
Analysis: Cells were fixed and permeabilised using a fix/perm solution (BD, Franklin 
Lakes, New Jersey, USA) followed by blocking with anti-mouse CD16/32 
(eBioscience, Thermo Scientific, Waltham, Massachusetts, USA) in PBS with 1% w/v 
BSA for 15 min at 4˚C. Cells were then incubated with lineage and stem 
cells/progenitor cell antibodies: anti-Lineage Mixture (mouse CD3e, CD11b, CD45R, 
Ly-6C/G, TER119, Invitrogen, Carlsbad, California, USA) and anti-Ly6-A/E (Sca-1), 
anti-Cd117 (c-Kit) (both from eBioscience), and rabbit anti-Neurokinin 1 Receptor 
(NK1R) (Novus Biologicals, Centennial, Colorado, USA) for 30 min at 4˚C. The 
concentration of primary antibodies is reported in ESM Table 1. Cells were then 
washed, treated with Goat Anti-Rabbit PE secondary antibodies for 30 min at 4˚C, and 
finally analysed using a FACS Canto II equipped with FACS Diva software (BD). 
 
BM cells migration 
To verify the effect of type 1 diabetes on the sensitivity of BM cells to SP, we performed 
in vitro migration assays using 6 well-plates transwell cell culture inserts equipped with 
3-5μm pore size filters (Corning, New York, USA). Freshly-isolated BM cells were 
plated onto the upper compartment (2.5x106, cells/well) and 100 mmol/l SP was added 
to the lower compartment in DMEM and 0.5% w/v foetal bovine serum. Cells were 
allowed to migrate overnight in a humidified atmosphere (37°C, 5% CO2). Cells from 
the upper (non-migrated cells) and lower compartments (migrated cells) were 
collected and processed for flow cytometry analysis with the use of AccuCheck 
counting beads (Invitrogen) for absolute and reproducible quantification of cell 
numbers. Enrichment of antigenically-defined cell populations was expressed as the 
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ratio of cells in lower and upper chambers and then normalised to control (cells treated 
with vehicle). 
 
Statistical analysis 
The D'Agostino & Pearson omnibus normality test was applied to check for normal 
distribution of data. Normally-distributed continuous variables were expressed as 
mean ± SEM and compared between groups using the unpaired Student t-test. When 
continuous variables did not follow a normal distribution, values were expressed as 
median (interquartile range IQR) and compared with the Wilcoxon-Mann-Whitney test. 
Categorical variables were compared using the chi-squared or the Fisher’s exact test. 
All reported p-values are two-sided. A p-value <0.05 was considered statistically 
significant. Statistical analyses were performed with STATA 11 software (StataCorp. 
2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP) or 
GraphPad Prism software, Version 6.01. 
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ESM Table 1. List of antibodies used in the experimental procedures 
 
Antibody Manufacturer 
Catalogue 
number 
IHC/ICC 
dilution 
(v/v) 
FACS 
dilution 
(v/v) 
WB 
dilution 
(v/v) 
Detection System 
IHC/ICC 
dilution 
(v/v) 
FACS/WB 
dilution 
(v/v) 
Rabbit anti-PGP 9.5 Millipore AB5925 1:500   
Peroxidase/DAB or TSA 
plus Fluorescein kit 
(NEL741E001KT) 
1:50  
Rabbit anti-Substance P Immunostar 22064 1:1500   
Peroxidase/DAB or TSA 
plus Fluorescein kit 
(NEL741E001KT) 
1:50  
Mouse anti-Substance P Abcam Ab14184 1:100   
Goat anti-mouse Alexa 
Fluor 546 
1:200  
Rabbit anti-NGF Abcam Ab6199 1:500   Peroxidase/DAB -  
Rabbit anti-NGF Abcam Ab52918 1:250   
Goat anti-rabbit Alexa 
Fluor 488 
1:200  
Rat anti-mouse CD31 
(MEC13.3) 
BD 
Pharmingen 
557355 1:100   
Goat anti-rat Alexa Fluor 
568 
1:300  
Isolectin B4 - Biotin Invitrogen 121414 1:100   
Streptavidin Alexa Fluor 
488 
1:200  
Mouse anti-CD3e, CD11b, 
CD45R, Ly-6C/G, TER119 
(Lineage cocktail) Alexa 
Fluor 488 
Invitrogen MLM20  1:100     
Rat anti-CD117 APC-
eFluor 780 
eBioscience 
Invitrogen 
47-1171-82  1-400     
Rat anti-mouse Ly-6A/E 
(Sca-1) APC 
eBioscience 
Invitrogen 
17-5981-83  1:400     
Rabbit anti-NK1 receptor 
Novus 
Biologicals  
NB300-
119B 
1:100   Goat anti-rabbit PE  1:200 
Rabbit anti-p75 Millipore AB1554 1:200   
Goat anti-rabbit Alexa 
Fluor 488 
1:200  
Rabbit anti-RET Abcam Ab134100 1:150   
Goat anti-rabbit Alexa 
Fluor 488 
1:200  
Rabbit anti-TRKA Abcam Ab76291 1:50  1:500 
Goat anti-rabbit Alexa 
Fluor 488 
Anti-rabbit IgG HRP 
1:200 1:5000 
Mouse anti-V5 Tag 
Thermo Fisher 
Scientific 
R960-25 1:150  1:1000 
Goat anti-mouse Alexa 
Fluor 546  
Anti-mouse IgG HRP 
1:200 1:5000 
Mouse anti-Substance P Abcam Ab14184 1:100   
Goat anti-mouse Alexa 
Fluor 546 
1:200  
Phospho-S6 Ribosomal 
Protein (Ser235/236) 
Cell Signaling 4858 1:300   
Goat anti-rabbit Alexa 
Fluor 488 
1:200  
Phosphor-TRKA (Tyr490) Cell Signaling 9141   1:500 Anti-rabbit IgG HRP  1:5000 
AKT (pan) (40D4) Cell Signaling 2920   1:1000 Anti-mouse IgG HRP  1:5000 
Phospho-AKT (Ser473) Cell Signaling 9271   1:1000 Anti-rabbit IgG HRP  1:5000 
Phospho-CREB 
(Ser133) 
Cell Signaling 9191   1:1000 Anti-rabbit IgG HRP  1:5000 
CREB (86B10) Cell Signaling 9104   1:1000 Anti-mouse IgG HRP  1:5000 
Phospho-p44/42 MAPK 
(ERK1/2) (Thr202/Tyr204) 
Cell Signaling 4370   1:1000 Anti-Rabbit IgG HRP  1:5000 
p44/42 MAPK (ERK1/2) 
(137F5) 
Cell Signaling 4695   1:1000 Anti-Rabbit IgG HRP  1:5000 
Phospho-p70 S6 Kinase 
(Thr421/Ser424) 
Cell Signaling 9204   1:1000 Anti-Rabbit IgG HRP  1:5000 
p70 S6 Kinase (49D7) Cell Signaling 2708   1:1000 Anti-Rabbit IgG HRP  1:5000 
Phospho-SAPK/JNK 
(Thr183/Tyr185) (81E11) 
Cell Signaling 4668   1:1000 Anti-Rabbit IgG HRP  1:5000 
SAPK/JNK Cell Signaling 9252   1:1000 Anti-Rabbit IgG HRP  1:5000 
β-Tubulin Cell Signaling 86298   1:5000 Anti-mouse IgG HRP  1:5000 
 
Antibodies validation: whenever possible, antibodies were previously validated by our team 
using positive or negative control tissues/cells. All antibodies used in this study have been 
previously used by other Investigators, and references are available either from the company 
or in online databases such as PubMed. The companies are often providing information on how 
antibodies specificity was tested.  
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ESM Figure 1  
 
Schematic cartoon showing signalling pathways associated with NGF 
receptors. NGF binds with high affinity the TrkA receptor that promotes cell survival 
and neural differentiation. At the opposite, proNGF binds with high affinity the p75NTR 
receptor, associated with cell death. 
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ESM Figure 2 
 
Schematic of the in vivo study experimental timeline. 
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ESM Figure 3  
 
 
Sensory fibres in mouse bone marrow express neurotrophins receptors. (a-c) 
Sensory fibres in mouse bone marrow (BM) were identified by staining for substance 
P (SP, red fluorescence). Co-staining for TrkA (a), p75NTR (b), and RET (c) receptors, 
all in green fluorescence, demonstrated sensory fibres innervating the BM are 
potentially responsive to neurotrophins stimuli. DAPI (blue) identifies nuclei. Scale bar, 
25 μm. Bone is identified by a dashed line.  
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ESM Figure 4 
 
Dorsal root ganglia express substance P. Immunofluorescence staining for 
substance P (green) in the spinal cord. Dorsal root ganglia (DRG) and dorsal horns 
(DH) are positive to SP. Scale bar, 10 μm. 
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ESM Figure 5 
 
Expression of NGF in PGP9.5 neuronal fibres. Immunohistochemistry staining for 
NGF (a) and PGP9.5 (b) on two consecutive slices of bone marrow indicates fibres 
co-express the 2 markers. Scale bar, 50 μm. 
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ESM Figure 6 
 
Competitive assay with NGF blocking peptide to test anti-NGF antibody 
(ab52918) specificity. a) control antibody; b) antibody pre-incubated with the NGF 
peptide. The neutralisation of the antibody prevented binding to the tissue. Images are 
provided at different magnification. Scale bar is 50 μm. 
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ESM Figure 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
 
Flow cytometry strategy. Illustration of the gating strategy in flow cytometry analyses 
of LSK cells. 
 
 
  
 15 
 
References 
[1] Emanueli C, Graiani G, Salis MB, Gadau S, Desortes E, Madeddu P (2004) 
Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia 
recovery in type 1 diabetic mice. Diabetes 53: 1096-1103 
[2] Emanueli C, Salis MB, Pinna A, et al. (2002) Prevention of diabetes-induced 
microangiopathy by human tissue kallikrein gene transfer. Circulation 106: 993-999 
[3] Graiani G, Emanueli C, Desortes E, et al. (2004) Nerve growth factor promotes 
reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of 
Type 1 diabetic mice. Diabetologia 47: 1047-1054 
[4] Kusano KF, Allendoerfer KL, Munger W, et al. (2004) Sonic hedgehog 
induces arteriogenesis in diabetic vasa nervorum and restores function in diabetic 
neuropathy. Arteriosclerosis, thrombosis, and vascular biology 24: 2102-2107 
[5] Kim H, Park JS, Choi YJ, et al. (2009) Bone marrow mononuclear cells have 
neurovascular tropism and improve diabetic neuropathy. Stem cells (Dayton, Ohio) 
27: 1686-1696 
[6] Anitha M, Gondha C, Sutliff R, et al. (2006) GDNF rescues hyperglycemia-
induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. The 
Journal of clinical investigation 116: 344-356 
[7] Madeddu P, Emanueli C, Spillmann F, et al. (2006) Murine models of 
myocardial and limb ischemia: diagnostic end-points and relevance to clinical 
problems. Vascular pharmacology 45: 281-301 
[8] Meloni M, Cesselli D, Caporali A, et al. (2015) Cardiac Nerve Growth Factor 
Overexpression Induces Bone Marrow-derived Progenitor Cells Mobilization and 
Homing to the Infarcted Heart. Mol Ther 23: 1854-1866 
 
